Breakthrough Hepatitis B Drug Achieves Functional Cure in 20% of Patients
New Hepatitis B drug may prevent cirrhosis, liver cancer with functional cure in 20% patients: Liver Doc explains breakthrough
The Indian Express
Image: The Indian Express
A new experimental drug, bepirovirsen, has shown promise in achieving a functional cure for hepatitis B in about 20% of patients during trials. This treatment could significantly impact the management of chronic hepatitis B, which affects millions globally, particularly in India. However, accessibility and diagnosis remain critical challenges.
- 01Bepirovirsen achieves a functional cure in approximately 20% of patients, particularly those with low virus antigen levels.
- 02The drug allows patients to control the virus without ongoing treatment, marking a significant advancement over current lifelong antiviral therapies.
- 03The treatment requires a six-month course of weekly injections, with potential side effects affecting 91% of participants.
- 04Only 13% of those with hepatitis B are diagnosed, highlighting the need for improved testing and awareness.
- 05The FDA is expected to make a decision on the drug by October 26, with potential implications for its rollout in healthcare systems.
Advertisement
In-Article Ad
In a significant advancement for hepatitis B treatment, the experimental drug bepirovirsen has demonstrated the ability to achieve a functional cure in about 20% of participants in clinical trials. This means that patients can maintain control over the virus without ongoing treatment. The findings, published in The New England Journal of Medicine, indicate that this drug could be a game changer for the 240 million people worldwide living with chronic hepatitis B, especially in countries like India, where an estimated 40 million are chronically infected. However, the treatment is not without challenges; it requires a six-month course of weekly injections, and side effects were reported in 91% of participants. Furthermore, the drug primarily benefits those with low virus antigen levels and no cirrhosis, emphasizing the need for widespread testing and diagnosis, as only 13% of affected individuals are currently diagnosed. The FDA is set to decide on the drug's approval by October 26, with hopes that it will improve management of hepatitis B, but affordability and access remain significant hurdles.
Advertisement
In-Article Ad
The introduction of bepirovirsen could transform the treatment landscape for hepatitis B, particularly in regions with high infection rates like India.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new hepatitis B treatment?
Connecting to poll...
Read the original article
Visit the source for the complete story.